Vinge advises Sobro in connection with the investment in NSS Group, a leading Nordic supplier of shelter solutions such as halls and tarpaulins.

NSS Group consists of Hallbyggarna Jonsereds (Sweden), Lainapeite (Finland) and IPS Hal & Presenning (Denmark). The group has a turnover of approximately SEK 300m and has 35 employees. NSS Group, with its roots in the 1950s, offers a modern and flexible range of products designed for the harsh Nordic climate and an international concept for logistics and procurement. Its customers are mainly found in the industrial and construction sectors.

Vinge’s team consisted of Johan Winnerblad, Elsie Nassar, Ellinor Wargenbrant and August Ahlin (M&A), Christoffer Nordin and Axel Lennartsson (Commercial Agreements), Karl-Gustaw Tobola (Banking and Financing), Kristoffer Larson (Real Estate and Environmental), Sara Passandideh (Employment), Nicklas Thorgerzon (IT and GDPR), Ian Jonsson (Intellectual Property) and Emelie Schoning (Project and VDR Assistant).

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025